Key terms
About ASLN
Aslan Pharmaceuticals Ltd. is a clinical-stage immunology biopharmaceutical company, which engages in the development of novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes ASLAN003 and Eblasakimab. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ASLN news
Mar 25
4:48pm ET
Aslan Pharmaceuticals files to sell 125M ordinary shares for holders
Mar 18
6:30am ET
Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Urogen Pharma (URGN) and Legend Biotech (LEGN)
Mar 18
6:13am ET
Aslan Pharmaceuticals price target lowered to $9 from $17 at H.C. Wainwright
Mar 15
11:32am ET
Biotech Alert: Searches spiking for these stocks today
Mar 14
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Mar 13
11:07am ET
Biotech Alert: Searches spiking for these stocks today
Mar 13
7:00am ET
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Legend Biotech (LEGN) and Aslan Pharmaceuticals (ASLN)
Mar 13
6:50am ET
Aslan Pharmaceuticals price target lowered to $10 from $15 at Piper Sandler
Mar 12
2:37pm ET
Aslan Pharmaceuticals announces $5M registered direct offering
Mar 11
2:45pm ET
Piper ‘confident’ partner or buyer will see benefit of Aslan’s eblasakimab
Mar 11
7:14am ET
Aslan Pharmaceuticals provides TREK-DX study update
Mar 06
7:11am ET
Aslan Pharmaceuticals announces new data on eblasakimab, appointments
Feb 29
7:20am ET
Aslan Pharmaceuticals receives favorable opintion from EPO on farudodstat
No recent news articles are available for ASLN
No recent press releases are available for ASLN
ASLN Financials
Key terms
Ad Feedback
ASLN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ASLN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range